ArticleAmerican journal of cancer research2025
Diagnostic and prognostic value of coagulation markers and platelet-derived growth factor-BB in evaluating intensity-modulated radiotherapy efficacy in nasopharyngeal carcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the diagnostic and prognostic value of coagulation markers - including activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FIB), platelet count (PLT), and D-dimer (DD) - and platelet-derived growth factor-BB (PDGF-BB) in patients with nasopharyngeal carcinoma (NPC) undergoing intensity-modulated radiotherapy (IMRT).
methodsA total of 210 NPC patients receiving IMRT and 160 healthy controls were enrolled. Baseline levels of PDGF-BB and coagulation markers were compared between groups. The association of PDGF-BB with clinical staging was analyzed, and receiver operating characteristic (ROC) curve analysis was used to assess its diagnostic performance. Cox regression analyses were performed to identify independent predictors of five-year survival. A dynamic nomogram was developed to provide individualized survival predictions.
resultsNPC patients exhibited significantly higher levels of PDGF-BB, APTT, PT, FIB, PLT, and DD compared to healthy controls (all P < 0.001). PDGF-BB was positively correlated with TNM stage (stage III/IV vs. I/II, P < 0.001), T stage (P = 0.005), and N stage (P = 0.020). Multivariate Cox regression identified low PDGF-BB (< 628.18) (HR = 0.492, P = 0.009), low DD (< 746.1) (HR = 0.456, P = 0.002), age 51-64 years (HR = 2.057, P = 0.032) and ≥ 65 years (HR = 4.138, P < 0.001), EBV DNA negativity (HR = 0.273, P = 0.012), and TNM stage III/IV (HR = 3.042, P = 0.023) as independent prognostic factors.
conclusionsPDGF-BB and DD, alongside age, EBV DNA status, and TNM stage, are promising biomarkers for NPC prognosis. A dynamic nomogram integrating these factors offers accurate survival prediction and supports personalized treatment strategies in NPC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.